Literature DB >> 6374279

[Circulating immune complexes before and after kidney allotransplantation].

G Keusch, H M Vonwiller, A von Felten, F Bammatter, H R Burger, F Largiadèr, U Binswanger.   

Abstract

In a prospective study circulating immune complexes (CIC) were analyzed before and serially after renal transplantation in 141 consecutive patients. CIC were measured using the Raji cell assay as originally described by Theofilopoulos and Dixon. The amount of CIC was expressed as microgram heat aggregated human immunoglobulin G (IgG) equivalent/ml serum. The upper limit of normal sera was 25 micrograms/ml. The values are expressed as geometric means (- 1 SD/ + 1 SD). In 86 of 133 rejection episodes a renal biopsy was performed and the histopathologic changes were semiquantitatively assessed and classified in a cellular or vascular type of rejection. Before transplantation CIC were detected in 104 of 141 patients (73.8%) and the mean value was 65.6 (27.8-154.9) micrograms/ml. The level of CIC was positively correlated with the number of grafts (r: 0.43; P less than 0.01) and the occurrence of chronic active hepatitis (r: 0.31; P less than 0.01). No correlation was found between CIC and the underlying kidney disease, the number of blood transfusions prior to transplantation, and the pre-existing lymphocytotoxic antibodies. Graft survival and number of rejection episodes were not influenced by the level of CIC prior to transplantation. After transplantation CIC were elevated in 60 patients (41%), appeared transiently in 49 patients (35%) and were never detectable in 32 patients (23%). In patients with a graft survival less than or equal to 11 months the average and peak post-transplant CIC levels were significantly higher than patients with a graft survival of 12 months: 64.4 (21.8-191.0); 87.7 (26.0-295.8) versus 39.6 (18.4-85.3); 56.8 (21.0-150.1) micrograms/ml; P less than 0.01.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6374279     DOI: 10.1007/bf01716255

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

1.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

2.  Complement components, degradation products and immune complexes after kidney transplantation.

Authors:  E Wegmüller; J Louis; J Hodler
Journal:  Proc Eur Dial Transplant Assoc       Date:  1978

3.  Immune complexes in acute and chronic liver disease.

Authors:  H C Thomas; D De Villiers; B Potter; H Hodgson; S Jain; D P Jewell; S Sherlock
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

4.  Association of a better kidney graft survival with the presence of circulating immune complexes before transplantation.

Authors:  N Carpentier; G Benzonana; M Jeannet; M Leski; P H Lambert
Journal:  Transplantation       Date:  1982-02       Impact factor: 4.939

5.  The detection of circulating immune complexes in renal transplant patients.

Authors:  M D Smith; P J Verroust; P J Griffin; J R Salaman
Journal:  Clin Exp Immunol       Date:  1980-01       Impact factor: 4.330

6.  The Raji cell radioimmune assay for detecting immune complexes in human sera.

Authors:  A N Theofilopoulos; C B Wilson; F J Dixon
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

7.  Circulating immune complexes after kidney transplantation.

Authors:  T Palosuo; K Kano; S Anthone; J R Gerbasi; F Milgrom
Journal:  Transplantation       Date:  1976-04       Impact factor: 4.939

8.  Circulating immune complexes after renal transplantation. Correlation of increased 125I-Clq binding activity with acute rejection characterized by fibrin deposition in the kidney.

Authors:  Y M Ooi; B S Ooi; E H Vallota; M R First; V E Pollak
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

9.  Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q.

Authors:  U E Nydegger; P H Lambert; H Gerber; P A Miescher
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

10.  Non-specificity of circulating immune complexes in patients with acute and chronic liver disease.

Authors:  C K Abrass; W A Border; G Hepner
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.